Sun Pharma Announces Top-Line Results from the Phase 2 Clinical Trials Evaluating SCD-044 for Moderate to Severe Psoriasis and Atopic Dermatitis
Recent Posts
- Sun Pharma reports Q1FY26 results
- Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
- Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
- Sun Pharma Brings Back Its #SecondBirthDate Campaign on National Doctors’ Day
- Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board
Recent Comments